BBOT
BridgeBio Oncology Therapeutics Inc.
Biotechnology
Market Cap$185M
5Y Perf.-24.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BBOT vs RVMD
Revenue, margins, valuation, and 5-year total return — side by side.
RVMD
Revolution Medicines, Inc.
Biotechnology
Market Cap$30.30B
5Y Perf.+383.4%
BBOT vs RVMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BBOT | RVMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $185M | $30.30B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-134M | $-1.37B |
| Total Debt | $3M | $159M |
| Cash & Equiv. | $374M | $384M |
BBOT vs RVMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BBOT
RVMD
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 75.9 | -24.1% |
| Revolution Medicine… (RVMD) | 100 | 483.4 | +383.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BBOT vs RVMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BBOT leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Revolution Medicines, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BBOT
BridgeBio Oncology Therapeutics Inc.
The Income Pick
BBOT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.96
- Lower volatility, beta 0.96, Low D/E 0.7%, current ratio 12.14x
- Beta 0.96, current ratio 12.14x
Best for: income & stability and sleep-well-at-night
RVMD
Revolution Medicines, Inc.
The Growth Play
RVMD is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth -66.2%
- 393.1% 10Y total return vs BBOT's -22.9%
- +278.4% vs BBOT's -27.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BBOT | -80.5% revenue growth vs RVMD's -98.6% |
| Stability / Safety | BBOT | Beta 0.96 vs RVMD's 1.08, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RVMD | +278.4% vs BBOT's -27.6% |
| Efficiency (ROA) | BBOT | -41.9% ROA vs RVMD's -59.1%, ROIC -96.3% vs -54.3% |
BBOT vs RVMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
BBOT vs RVMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRVMDLAGGINGBBOT
BBOTBridgeBio Oncology Th…
1leads
RVMDRevolution Medicines,…
2leads
6 Total Categories
CATEGORYLEADERvs BBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RVMD1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BBOT7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RVMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RVMD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BBOT and RVMD operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | RVMDRevolution Medici… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$166M | -$1.4B |
| Net IncomeAfter-tax profit | -$134M | -$1.4B |
| Free Cash FlowCash after capex | -$95M | -$1.1B |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -21.2% | -102.7% |
RVMD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BBOT and RVMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BBOTBridgeBio Oncolog… | RVMDRevolution Medici… |
|---|---|---|
| Market CapShares × price | $185M | $30.3B |
| Enterprise ValueMkt cap + debt − cash | -$186M | $30.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.83x | -23.95x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.60x | 16.61x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BBOT and RVMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
BBOT leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
BBOT delivers a -65.5% return on equity — every $100 of shareholder capital generates $-66 in annual profit, vs $-83 for RVMD. BBOT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), BBOT scores 4/9 vs RVMD's 1/9, reflecting mixed financial health.
| Metric | BBOTBridgeBio Oncolog… | RVMDRevolution Medici… |
|---|---|---|
| ROE (TTM)Return on equity | -65.5% | -83.2% |
| ROA (TTM)Return on assets | -41.9% | -59.1% |
| ROICReturn on invested capital | -96.3% | -54.3% |
| ROCEReturn on capital employed | -48.0% | -53.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.01x | 0.10x |
| Net DebtTotal debt minus cash | -$371M | -$225M |
| Cash & Equiv.Liquid assets | $374M | $384M |
| Total DebtShort + long-term debt | $3M | $159M |
| Interest CoverageEBIT ÷ Interest expense | — | -81.62x |
BBOT leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RVMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RVMD five years ago would be worth $48,210 today (with dividends reinvested), compared to $7,713 for BBOT. Over the past 12 months, RVMD leads with a +278.4% total return vs BBOT's -27.6%. The 3-year compound annual growth rate (CAGR) favors RVMD at 80.0% vs BBOT's -8.3% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | RVMDRevolution Medici… |
|---|---|---|
| YTD ReturnYear-to-date | -36.0% | +80.3% |
| 1-Year ReturnPast 12 months | -27.6% | +278.4% |
| 3-Year ReturnCumulative with dividends | -22.9% | +483.1% |
| 5-Year ReturnCumulative with dividends | -22.9% | +382.1% |
| 10-Year ReturnCumulative with dividends | -22.9% | +393.1% |
| CAGR (3Y)Annualised 3-year return | -8.3% | +80.0% |
RVMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BBOT and RVMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
BBOT is the less volatile stock with a 0.96 beta — it tends to amplify market swings less than RVMD's 1.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 91.5% from its 52-week high vs BBOT's 52.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | RVMDRevolution Medici… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 1.08x |
| 52-Week HighHighest price in past year | $14.87 | $155.70 |
| 52-Week LowLowest price in past year | $7.63 | $34.00 |
| % of 52W HighCurrent price vs 52-week peak | +52.9% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 66.4 |
| Avg Volume (50D)Average daily shares traded | 306K | 2.9M |
Evenly matched — BBOT and RVMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BBOT as "Buy" and RVMD as "Buy". Consensus price targets imply 175.7% upside for BBOT (target: $22) vs 8.6% for RVMD (target: $155).
| Metric | BBOTBridgeBio Oncolog… | RVMDRevolution Medici… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.67 | $154.80 |
| # AnalystsCovering analysts | 3 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RVMD leads in 2 of 6 categories (Income & Cash Flow, Total Returns). BBOT leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallRevolution Medicines, Inc. (RVMD)Leads 2 of 6 categories
Loading custom metrics...
BBOT vs RVMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BBOT or RVMD a better buy right now?
Analysts rate BridgeBio Oncology Therapeutics Inc.
(BBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BBOT or RVMD?
Over the past 5 years, Revolution Medicines, Inc.
(RVMD) delivered a total return of +382. 1%, compared to -22. 9% for BridgeBio Oncology Therapeutics Inc. (BBOT). Over 10 years, the gap is even starker: RVMD returned +393. 1% versus BBOT's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BBOT or RVMD?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc.
(BBOT) is the lower-risk stock at 0. 96β versus Revolution Medicines, Inc. 's 1. 08β — meaning RVMD is approximately 13% more volatile than BBOT relative to the S&P 500. On balance sheet safety, BridgeBio Oncology Therapeutics Inc. (BBOT) carries a lower debt/equity ratio of 1% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BBOT or RVMD?
On earnings-per-share growth, the picture is similar: Revolution Medicines, Inc.
grew EPS -66. 2% year-over-year, compared to -1034. 8% for BridgeBio Oncology Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BBOT or RVMD?
BridgeBio Oncology Therapeutics Inc.
(BBOT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Revolution Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BBOT leads at 0. 0% versus 0. 0% for RVMD. At the gross margin level — before operating expenses — BBOT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BBOT or RVMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BBOT or RVMD better for a retirement portfolio?
For long-horizon retirement investors, Revolution Medicines, Inc.
(RVMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), +393. 1% 10Y return). Both have compounded well over 10 years (RVMD: +393. 1%, BBOT: -22. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BBOT and RVMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.